Elanco Animal Health Incorporated (ELAN) Investor Relations Documents

Elanco Animal Health Incorporated (ELAN) investor relations documents from the company's IR site: 3 presentations, 27 press releases; latest deck 2026-06-19. Read in-app with summaries. First-party data.

PDF Version: Elanco Animal Health reported 2025 revenue of $4.715 billion and raised its 2026 innovation revenue target to $1.15 billion.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-17DocumentPDF Version
2026-08-17DocumentPDF Version
2026-08-17DocumentPDF Version
2026-08-17DocumentPDF Version
2026-08-17DocumentPDF Version
2026-08-17DocumentPDF Version
2026-08-17DocumentPDF Version
2026-08-17DocumentPDF Version
2026-08-17DocumentPDF Version
2026-08-17DocumentPDF Version
2026-08-17Press releasePDF Version
2026-08-17Press releasePDF Version
2026-08-07Press releaseElanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Applicatio
2026-08-05Press releasePDF Version
2026-08-05Press releaseElanco Animal Health Reports Second Quarter 2026 Results
2026-07-31Press releasePDF Version
2026-07-22Press releasePDF Version
2026-07-22Press releaseCredelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simpari
2026-07-08Press releasePDF Version
2026-07-08Press releaseElanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement
2026-06-19PresentationPDF Version
2026-06-18Press releasePDF Version
2026-06-18Press releaseElanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health
2026-06-15Press releasePDF Version
2026-06-15Press releaseElanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Lept
2026-06-04Press releasePDF Version
2026-06-04Press releaseElanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm
2026-06-03Press releasePDF Version
2026-06-03Press releaseNew Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience
2026-06-02PresentationWilliam-Blair-ELAN-2-June-2026-vF.pdf
2026-05-18Press releasePDF Version
2026-05-18Press releaseElanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion
2026-05-14Press releasePDF Version
2026-05-14Press releaseElanco to Participate in Upcoming Investor Conferences
Press releaseElanco Animal Health Reports First Quarter 2026 Results
2026-05-06Press releasePDF Version
2026-05-05Earnings deckQ1 2026 Earnings Presentation
2026-05-05Press releaseQ1 2026 Earnings Release
2026-04-27Press releasePDF Version
2026-04-27Press releaseElanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive

ELAN overview · ELAN earnings · ELAN financials · ELAN KPIs · ELAN documents · ELAN ownership · ELAN peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.